New Green and High-throughput Microwell Spectrophotometric Method
for Quality Control of Pharmaceutical Formulations of Selective
Serotonin Reuptake Inhibitors via Microscale Formation of their
N-Vinylamino-naphthoquinone Derivatives

Reem   M.   Abuhejail; Nourah   Z.   Alzoman; Ibrahim   A.   Darwish

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) are mostly prescribed for the treatment of depression. This study describes the microscale in-microwell formation of blue-colored N-vinylamino-naphthoquinone derivatives of SSRIs upon their reaction with 2,3-dichloro-1,4- naphthoquinone (DCNQ) and acetaldehyde. The reaction was subsequently utilized as a basis for the development of a new simple and sensitive microwell spectrophotometric method (MW-SPM) for the quality control of pharmaceutical formulations of four SSRIs. These SSRIs are fluoxetine (FLU), sertraline (SER), paroxetine (PAR), and reboxetine (REB).

Methods: The MW-SPM procedure was performed in 96-microwell transparent plates, and the microplate reader was employed to measure the absorbances of the reaction products at their peak absorbance wavelength of 580 nm. The best conditions for the method were determined.

Results: The relations showed good linearity (correlation coefficients were ≥0.9992) in the concentration range of 5 – 600 μg/mL. The limits of detection ranged from 5.20 to 15.58 μg/mL. The precision was deemed acceptable since all cases' relative standard deviation (RSD) values remained below 2.21%. Recovery experiments were conducted to confirm the accuracy of the method, yielding recovery values of at least 97.8%. The MW-SPM method was effectively utilized to analyze SSRIs in both their bulk and pharmaceutical dosage forms, exhibiting acceptable accuracy and precision. The recovery values ranged from 99.4% to 101.0% (with a margin of error of ± 0.5% to 1.6%). The results were comparable with those of the pre-validated reported methods. Four different metric tools evaluated the greenness of the proposed method, and the results proved that the method fulfills the requirements of green analytical approaches. Furthermore, the ability to handle numerous microvolume samples simultaneously in the described method provides it with a high-throughput characteristic.

Conclusion: The proposed MW-SPM represents a valuable tool for an efficient analysis of SSRIs in pharmaceutical quality control units.

Keywords: SSRIs, spectrophotometry, microwell method, green analytical approach, high-throughput analysis, N-vinylaminonaphthoquinone derivatives.

Graphical Abstract

[1]
 World Health Organization. Available from: https://www.who.int/health-topics/depression#tab=tab_1 (Accessed on 29 March 2023).

[2]
Ford, S.M. Introduction to Clinical Pharmacology, 12th ed; Lippincott Williams & Wilkins: Philadelphia, 2021. 

[3]
Eyewitness, D.K. The British Medical Association, Illustrated Medical Dictionary, 3rd ed; Adorling Kindersley Ltd.: London, 2013. 

[4]
Quevedo, J.; Zarate, C.A., Jr; Carvalho, A.F. Neurobiology of depression: road to novel therapeutics; Academic Press, Elsevier Inc.: London, UK, 2019. 

[5]
Tundo, A.; Filippis, R.; Proietti, L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J. Psychiatry,  2015, 5(3), 330-341.
 [http://dx.doi.org/10.5498/wjp.v5.i3.330] [PMID: 26425446]

[6]
Roiser, J.P.; Elliott, R.; Sahakian, B.J. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology,  2012, 37(1), 117-136.
 [http://dx.doi.org/10.1038/npp.2011.183] [PMID: 21976044]

[7]
Leahy, R.L.; Holland, S.J.F.; McGinn, L.K. Treatment plans and interventions for depression and anxiety disorders, 2nd ed; Guilford Publications: New York, USA, 2011. 

[8]
Radenković, M.Ć. Novel approaches in treating major depressive disorder (depression); Nova Medicine & Health, 2019. 

[9]
Preskorn, S.H. Clinical pharmacology of selective serotonin reuptake inhibitors, 1st ed; Professional Communications, Inc.: New York, USA, 1996. 

[10]
Sabri, R. The addictive potential of selective serotonin reuptake inhibitors: addictive potential of selective serotonin reuptake inhibitors relative to benzodiazepines in UK psychiatric patients; LAP Lambert Academic Publishing: London, UK, 2011. 

[11]
Şentürk, Z.; Saka, C.; Teğin, İ. Analytical methods for determination of selective serotonin reuptake inhibitor antidepressants. Rev. Anal. Chem.,  2011, 30(2), 87-122.
 [http://dx.doi.org/10.1515/revac.2011.018]

[12]
Jia, E.; Bartlett, M.G. Recent advances in liquid chromatographic methods for the determination of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. Biomed. Chromatogr.,  2020, 34(3), e4760.
 [http://dx.doi.org/10.1002/bmc.4760] [PMID: 31758582]

[13]
Darwish, I.A.; Refaat, I.H. Spectrophotometric analysis of selective serotonin reuptake inhibitors based on formation of charge-transfer complexes with tetracyanoquinodimethane and chloranilic acid. J. AOAC Int.,  2006, 89(2), 326-333.
 [http://dx.doi.org/10.1093/jaoac/89.2.326] [PMID: 16640280]

[14]
Soliman, S.M.; Mohamed, T.A. Spectrophotometric and spectrofluorimetric determination of some selective serotonin reuptake inhibitors [SSRIs] through ternary complex formation with eosin and copper [II] in pharmaceuticals. J. Drug Res. Egypt,  2011, 32, 111-121.

[15]
Emin, C.; Rodica, S.; Ionescu, A.M.; Safta, A.; Tomescu, C.L. Validation of a spectrophotometric method of some antidepressant drugs. Europ. J. Nat. Sci. Med.,  2023, 6(1), 1-9.
 [http://dx.doi.org/10.2478/ejnsm-2023-0001]

[16]
Annapurna, V.; Jyothi, G.; Rohini Kumari, T.; Sailaja, B.B.V. Spectrophotometric determination of various drugs using chloranilic acid as chromogenic reagent – II. E-J. Chem.,  2010, 7(2), 624-628.
 [http://dx.doi.org/10.1155/2010/306858]

[17]
Rao, A.L.; Rajeswari, K.R.; Sankar, G.G. Spectrophotometric methods for the determination of selected drugs in pharmaceutical formulations. J. Chem. Pharm. Res.,  2010, 2, 280-282.

[18]
Annapurna, M.M.; Pradhan, D.P. New derivative spectrophotometric methods for the determination of fluoxetine - an antidepressant drug. Chem. Sci. Trans.,  2012, 1(3), 697-701.
 [http://dx.doi.org/10.7598/cst2012.225]

[19]
Constantinescu, I.C.; Florea, M.; Neagu, A.F. Development of a spectrophotometric method for determination of fluoxetine hydrochloride in bulk and pharmaceutical dosage forms. Farmacia,  2015, 63, 816-820.

[20]
Mukhopadhyay, A.; Pradhan, K.K.; Samanta, R. Development and validation of an UV-spectrophotometric method for the estimation of fluoxetine in pure and tablet dosage forms. Int. J. Pharm. Sci. Res.,  2014, 5, 3418-3424.

[21]
Darwish, I.A. Development and validation of spectrophotometric methods for determination of fluoxetine, sertraline, and paroxetine in pharmaceutical dosage forms. J. AOAC Int.,  2005, 88(1), 38-45.
 [http://dx.doi.org/10.1093/jaoac/88.1.38] [PMID: 15759724]

[22]
Affas, S.; Sakur, A.A. Spectrophotometric method for simultaneous estimation of dapoxetine and some phosphodiesterase-5 inhibitors in new combinations. Res. J. Pharm. Technol.,  2019, 12(11), 5193-5198.
 [http://dx.doi.org/10.5958/0974-360X.2019.00899.0]

[23]
Görög, S. Ultraviolet-visible spectrophotometry in pharmaceutical analysis; CRC Press: New York, NY, USA, 2018. 
 [http://dx.doi.org/10.1201/9781351077422]

[24]
Ahmed, S.; Rasul, A.; Masood, Z. Spectrophotometry in pharmaceutical analysis; LAP Lambert Academic Publishing: London, 2011. 

[25]
Gore, M.G. Spectrophotometry and spectrofluorimetry: A practical approach, 2nd ed; Oxford University Press: Oxford, 2000. 
 [http://dx.doi.org/10.1093/oso/9780199638130.001.0001]

[26]
Wang, P.G. High-throughput analysis in the pharmaceutical industry, 1st ed; CRC Press, 2019. 

[27]
Mennen, S.M.; Alhambra, C.; Allen, C.L.; Barberis, M.; Berritt, S.; Brandt, T.A.; Campbell, A.D.; Castañón, J.; Cherney, A.H.; Christensen, M.; Damon, D.B.; Eugenio de Diego, J.; García-Cerrada, S.; García-Losada, P.; Haro, R.; Janey, J.; Leitch, D.C.; Li, L.; Liu, F.; Lobben, P.C.; MacMillan, D.W.C.; Magano, J.; McInturff, E.; Monfette, S.; Post, R.J.; Schultz, D.; Sitter, B.J.; Stevens, J.M.; Strambeanu, I.I.; Twilton, J.; Wang, K.; Zajac, M.A. The evolution of high-throughput experimentation in pharmaceutical development and perspectives on the future. Org. Process Res. Dev.,  2019, 23(6), 1213-1242.
 [http://dx.doi.org/10.1021/acs.oprd.9b00140]

[28]
Darwish, I.A.; Alzoman, N.Z. Development and validation of green and high-throughput microwell spectrophotometric assay for the determination of selective serotonin reuptake inhibitors in their pharmaceutical dosage forms. Molecules,  2023, 28(10), 4221.
 [http://dx.doi.org/10.3390/molecules28104221] [PMID: 37241961]

[29]
Wennborg, H.; Bonde, J.P.; Stenbeck, M.; Olsen, J. Adverse reproduction outcomes among employees working in biomedical research laboratories. Scand. J. Work Environ. Health,  2002, 28(1), 5-11.
 [http://dx.doi.org/10.5271/sjweh.640] [PMID: 11871853]

[30]
Lindbohm, M.L.; Taskinen, H.; Sallman, M.; Hemminki, K. Spontaneous abortions among women exposed to organic solvents. Am. J. Ind. Med.,  1990, 17(4), 449-463.
 [http://dx.doi.org/10.1002/ajim.4700170404] [PMID: 2327413]

[31]
Wennborg, H.; Bodin, L.; Vainio, H.; Axelsson, G. Pregnancy outcome of personnel in Swedish biomedical research laboratories. J. Occup. Environ. Med.,  2000, 42(4), 438-446.
 [http://dx.doi.org/10.1097/00043764-200004000-00022] [PMID: 10774513]

[32]
Kristensen, P.; Hilt, B.; Svendsen, K.; Grimsrud, T.K. Incidence of lymphohaematopoietic cancer at a university laboratory: a cluster investigation. Eur. J. Epidemiol.,  2008, 23(1), 11-15.
 [http://dx.doi.org/10.1007/s10654-007-9203-5] [PMID: 17985198]

[33]
ICH. International council for harmonisation of technical requirements for pharmaceuticals for human use, ICH Harmonised guideline, validation of analytical procedure: Q2(R2); ICH: Geneva, Switzerland, 2022. 

[34]
The United States Pharmacopoeia-National Formulary (USP-NF). US Pharmacopeial Convention Rockville; MD, 2021. 

[35]
Keith, L.H.; Gron, L.U.; Young, J.L. Green analytical methodologies. Chem. Rev.,  2007, 107(6), 2695-2708.
 [http://dx.doi.org/10.1021/cr068359e] [PMID: 17521200]

[36]
Gałuszka, A.; Migaszewski, Z.M.; Konieczka, P.; Namieśnik, J. Analytical Eco-Scale for assessing the greenness of analytical procedures. Trends Analyt. Chem.,  2012, 37, 61-72.
 [http://dx.doi.org/10.1016/j.trac.2012.03.013]

[37]
Płotka-Wasylka, J. A new tool for the evaluation of the analytical procedure. Green Analytical Procedure Index. Talanta,  2018, 181, 204-209.
 [http://dx.doi.org/10.1016/j.talanta.2018.01.013] [PMID: 29426502]

[38]
Pena-Pereira, F.; Wojnowski, W.; Tobiszewski, M. AGREE-analytical greenness metric approach and software. Anal. Chem.,  2020, 92(14), 10076-10082.
 [http://dx.doi.org/10.1021/acs.analchem.0c01887] [PMID: 32538619]

[39]
Hussein, S.A. Spectrophotometric determination of trimetazidine hydrochloride. Alex. J. Pharm. Sci.,  2002, 16, 39-44.

Cite As

Current Analytical Chemistry

New Green and High-throughput Microwell Spectrophotometric Method for Quality Control of Pharmaceutical Formulations of Selective Serotonin Reuptake Inhibitors via Microscale Formation of their N-Vinylamino-naphthoquinone Derivatives

Abstract

Graphical Abstract